Micro-X Ltd (ASX:MX1) Reports Q4 Strategic Realignment and Financial Highlights
Micro-X Ltd (ASX:MX1) realigns strategy towards Medical CT, secures $25m ARPA-H funding, and achieves key product milestones in Q4.
Category: Healthcare
Echo IQ Limited (ASX:EIQ) Submits Pre-Submission Meeting Request with US FDA
Echo IQ Limited (ASX:EIQ) submits a pre-submission meeting request with the US FDA for its heart failure solution, EchoSolv HF, progressing towards market entry in H2 2025.
Wellnex Life Limited (ASX:WNX) Q2 FY25 Sales Surge and UK Expansion
Wellnex Life Limited (ASX:WNX) reports a 112% sales increase in 1H FY25 and announces progress in its UK market expansion and dual listing on the London Stock Exchange.
Cann Group Limited (ASX:CAN) Announces Q2 2024 Results
Cann Group Limited (ASX:CAN) announces Q2 2024 results, highlighting improved cash flow, increased production, and plans for future growth.
Emyria Limited (ASX:EMD) Announces Q4 2024 Quarterly Highlights
Emyria Limited (ASX:EMD) reports Q4 2024 achievements in mental health treatments, strategic partnerships, and a successful $2.525M placement.
Clarity Pharmaceuticals (ASX:CU6) Releases Q4 Activity Report
Clarity Pharmaceuticals (ASX:CU6) reports strong Q4 financials, significant trial progress, and entry into the ASX200 index.
Tissue Repair Limited (ASX:TRP) Announces Q4 2024 Progress and Financial Results
Tissue Repair (ASX:TRP) reports strong Q4 2024 progress in drug trials and a 35% increase in TR Pro+® sales.
HITIQ Limited (ASX:HIQ) Converts $1.6m Notes to Shares and Secures New Advisory Mandate
HITIQ Limited (ASX:HIQ) converts $1.6m in notes into shares and secures a new advisory mandate to enhance US investor relations.
Chimeric Therapeutics Limited (ASX:CHM) Reports Q4 Activities
Chimeric Therapeutics (ASX:CHM) advances clinical trials, secures $5M in funding, and appoints Dr Rebecca McQualter as CEO in Q4 report.
Arovella Therapeutics Limited (ASX:ALA) Raises $20M to Fund Phase 1 Clinical Trials
Arovella Therapeutics (ASX:ALA) secures $20 million placement, fully funding Phase 1 trials for ALA-101 and advancing its cancer therapy pipeline.